SUBSCRIBE
SUBSCRIBE
News   Drug Development

FDA Advisers Vote Against Procter & Gamble’s Female Sex Drug

October 19, 2005 | 
1 min read

Procter & Gamble Co.'s testosterone patch for boosting female sex drive needs longer-term testing for serious side effects before it can win approval, a U.S. advisory panel unanimously ruled on Thursday.

Clinical research Phase III FDA Approvals Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Amgen sign at its headquarters in Thousand Oaks, California, USA.
Approvals
Looking Beyond Obesity, Amgen Wins Colorectal Cancer Expansion for Lumakras
January 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Boehringer Ingelheim sign on a building/
Schizophrenia
Boehringer Suffers Phase III Schizophrenia Fail, Legal Parry by HHS
January 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Exterior view of the headquarters of the
Complete response letters
Manufacturing Issues Result in FDA Rejection of Atara’s Cell Therapy
January 16, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
FDA signage at its headquarters in Maryland
Regulatory
After Letter to Commissioner, FDA Finally Gives Vanda Reason for Rejection, Chance for Hearing
January 16, 2025
 · 
2 min read
 · 
Tristan Manalac